MCM
DYN icon

MAI Capital Management’s Dyne Therapeutics DYN Stock Holding History

MAI Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.05K Buy
+113
New +$1.95K ﹤0.01% 3913
2025
Q2 		– Sell
-45
Closed -$471 – 3980
2025
Q1 		$471 Buy
+45
New +$644 ﹤0.01% 3241

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

MAI Capital Management's DYN Position: Q1 2026 in Review

MAI Capital Management opened a new position in Dyne Therapeutics (DYN) in Q1 2026: 113 shares worth $2.05K. The stake represents ﹤0.01% of the portfolio and ranks #3913 among its holdings. This is a return to the name: MAI Capital Management previously reported a position in DYN as recently as Q1 2025.

MAI Capital Management first reported a position in DYN in Q1 2025 and has held it in 2 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • MAI Capital Management held 113 shares of Dyne Therapeutics worth $2.05K as of Q1 2026.
  • Dyne Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Dyne Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #3913 holding.
  • MAI Capital Management first reported a position in Dyne Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.